Abstract: In certain embodiments, the present disclosure is directed to methods and uses of flunarizine, including for treating absence seizures in a human patient, such as absence seizures in childhood absence epilepsy (CAE), wherein the methods comprise administering (e.g., orally) to a patient in need thereof a therapeutically effective amount of flunarizine. The present disclosure is further directed to various improved methods of therapy and administration of flunarizine.

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.

Abstract: Detergent compositions or components are formulated with certain hydrophobically modified cellulosic materials, which provide protection of fabrics, whereof at least 80% or even at least 90% have a particle size of below 1000 microns or even below 850 or even 710 microns. Selection of materials of this particle size results in improved dispersability of the cellulosic material and imparts improved appearance and integrity benefits to fabrics and textiles laundered in washing solutions from such compositions.